This article is more than 5 years old. Information may no longer be current.

NanoVision announces license agreement, technology collaboration with OVI Lens

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NanoVision Group announced it has entered into a manufacturing and distribution agreement with OVI Lens, as well as a collaboration for new technological development.

Under the agreement, OVI Lens is permitted to manufacture bandage and therapeutic contact lenses under the umbrella of NanoVision. Additionally, the agreement enables NanoVision to distribute OVI’s Quotidia Therapeutic, Quotidia Daily Aloe, Quotidia Therapeutic Aloe and Quotidia Schleral Aloe contact lenses in Asia, Europe and the Middle East on an exclusive or co-exclusive basis starting Sept. 24, according to a press release.

“Part of our growth strategy is to broaden our product portfolio and meet the growing demands of both hospitals and ambulatory surgery centers,” Dimitrii Dementiev, MD, chairman of NanoVision Group, said in the release. “This strategic alliance will enhance our manufacturing supply chain efficiency and accelerate new product development.”